- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.09. | Reviva Pharmaceuticals: Schizophrenie-Kandidat Brilaroxazin mit Fortschritten | 5 | Investing.com Deutsch | ||
| 12.08. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.08. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 12.08. | Reviva Pharmaceuticals GAAP EPS of -$0.19 beats by $0.17 | 3 | Seeking Alpha | ||
| 12.08. | Reviva Pharmaceuticals: Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights | 313 | GlobeNewswire (Europe) | - U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback... ► Artikel lesen | |
| 10.07. | NSE - REVIVA PHARMACEUTICALS HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 6 | SEC Filings | ||
| 13.05. | Reviva Pharmaceuticals GAAP EPS of -$0.46 misses by $0.11 | 4 | Seeking Alpha | ||
| 13.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 13.05. | Reviva Pharmaceuticals: Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | 448 | GlobeNewswire (Europe) | - Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form... ► Artikel lesen | |
| 13.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 6 | SEC Filings | ||
| 15.04. | Reviva Pharmaceuticals sichert sich 10 Mio. US-Dollar und verlängert finanzielle Reichweite bis Q1 2027 | 1 | Investing.com Deutsch | ||
| 15.04. | Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 | 1 | Investing.com | ||
| 15.04. | Reviva Pharmaceuticals: Reviva Announces Letter to Shareholders | 672 | GlobeNewswire (Europe) | CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies... ► Artikel lesen | |
| 15.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | Reviva Pharmaceuticals: Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | 427 | GlobeNewswire (Europe) | - Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia - - Current data package highlights... ► Artikel lesen | |
| 25.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering | 262 | GlobeNewswire (Europe) | CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that... ► Artikel lesen | |
| 23.12.25 | Reviva Pharmaceuticals: Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia | 712 | GlobeNewswire (Europe) | Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the... ► Artikel lesen | |
| 13.11.25 | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 1.296 | GlobeNewswire (Europe) | - Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 - - Potential NDA submission for schizophrenia indication targeted for Q2 2026 - - European... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 43,960 | -2,18 % | Bayer Aktie stürzt ab: Verkaufssignale, doch JPMorgan hält dagegen | Die Bayer Aktie ist am Donnerstag massiv unter Druck geraten. Der Kurs des Leverkusener Pharma- und Agrarkonzerns brach auf XETRA-Schlusskursbasis um 2,55 Euro oder 5,32 Prozent auf 45,40 Euro ein und... ► Artikel lesen | |
| NOVO NORDISK | 33,685 | +0,70 % | Novo Nordisk zahlt bis zu 2,6 Milliarden Dollar für Biotech - warum Eli Lilly, GSK und AstraZeneca ebenfalls Milliarden auf neue Technologien setzen | ||
| ROCHE | 373,36 | -0,09 % | Vom Brainshuttle zur Rückenmarksflüssigkeit: Wie Roche, Denali und NurExone Wirkstoffe ins Nervensystem bringen | ||
| VIATRIS | 15,614 | -0,56 % | UBS erhöht Kursziel für Viatris wegen Cenerimod-Aussichten | ||
| SYNBIOTIC | 0,805 | -1,83 % | Original-Research: SYNBIOTIC SE (von NuWays AG): Under review | Original-Research: SYNBIOTIC SE - from NuWays AG
24.08.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,810 | -2,41 % | ORGANIGRAM GLOBAL INC. - 6-K, Report of foreign issuer | ||
| GREEN THUMB INDUSTRIES | 5,930 | +1,37 % | Green Thumb Industries Reports Second Quarter 2026 Results | CHICAGO and VANCOUVER, British Columbia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 7,300 | +1,67 % | Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report | ||
| NEWRON PHARMACEUTICALS | 8,360 | -2,11 % | Newron Aktie: FDA-Entscheidung bleibt der Belastungsfaktor | Bei Newron Pharmaceuticals bleibt der nicht aufgehobene Zulassungsstopp für die Aufnahme von US-Patienten in die ENIGMA-TRS-2-Studie mit Evenamide das zentrale Thema. Die Einschränkung betrifft weder... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,815 | +5,16 % | XFRA PX91: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 4,000 | -0,12 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| COMPASS PATHWAYS | 10,400 | 0,00 % | Compass Pathfinder Limited: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,300 | -0,96 % | SONDERMELDUNG: Könnte die Aktie von SELLAS Life Sciences Group Inc jetzt komplett einbrechen? - Jetzt handeln, noch vor dem Wochenende! | ||
| OPKO HEALTH | 1,420 | +0,71 % | OPKO HEALTH, INC. - 8-K, Current Report | ||
| XORTX THERAPEUTICS | 1,470 | 0,00 % | XORTX Therapeutics Inc.: XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO, Targeting USD$700M+ U.S. Gout Market Opportunity | CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative... ► Artikel lesen |
REVIVA PHARMACEUTICALS HOLDINGS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -0,20 % bei einem Aktienkurs von 0,351 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.